Saturday, October 31, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 12, 2026

Orion Group Financial Statement Release January–December 2025

View original at globenewswire.com
Orion Group Financial Statement Release January–December 2025 ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October–December 2024: 434.4) million Operating…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The outlook for 2026 does not include any material milestone payments

    80% confidence

  • Sales and marketing expenses are expected to increase in 2026

    80% confidence

  • R&D costs in 2026 will increase from 2025

    80% confidence

  • Animal Health business division is anticipated to grow slightly in 2026

    80% confidence

  • Nubeqa has consistently exceeded expectations, and Orion's annual Nubeqa net sales have the potential to exceed EUR 1 billion by the end of the current decade

    80% confidence

  • Total capital expenditure in 2026 is not expected to have significant changes compared to 2025

    80% confidence

  • Nubeqa royalties and product sales booked by Orion will increase clearly in 2026

    80% confidence

  • Expecting another very strong year in 2026 with continued determined work to build well-being and Orion's future

    80% confidence

  • Orion aims to expand the ODM-212 phase 2 program during 2026

    80% confidence

  • ODM-212 has a lot of potential with its mode of action in various indications beyond rare cancers

    80% confidence

  • Orion delivered a very strong performance in 2025 with solid financial results and clear progress in executing strategy

    80% confidence

  • Branded Products business division is estimated to grow in 2026, driven by Respiratory therapy area and Easyhaler portfolio

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com